Last reviewed · How we verify

Postoperative pain — Treatment Landscape & Competitive Intelligence

Postoperative pain (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Postoperative pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Journavx SUZETRIGINE Vertex Pharms Inc Sodium Channel Blocker [EPC] 2025-01-01
Sufenta Preservative Free SUFENTANIL Rising Opioid Agonist Mu-type opioid receptor 1984-01-01
Sulfentanyl Sulfentanyl Shenzhen Third People's Hospital Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor
Sulfentanil Sulfentanil Henan Provincial People's Hospital Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Henan Provincial People's Hospital · 1 drug in Postoperative pain
  2. Rising · 1 drug in Postoperative pain
  3. Shenzhen Third People's Hospital · 1 drug in Postoperative pain
  4. Vertex Pharms Inc · 1 drug in Postoperative pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Postoperative pain:

Cite this brief

Drug Landscape (2026). Postoperative pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/postoperative-pain. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing